MedTrace Logo

Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

NCT03891706 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-09-19

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor .

The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .

Conditions

Interventions

DRUG

tumor-specific TCR-T cells

On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.

DRUG

Interleukin-2

Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Guangzhou FineImmune Biotechnology Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Penghui Zhou · Guangzhou FineImmune Biotechnology Co., LTD.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-08
Primary Completion
2025-10-01
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03891706 on ClinicalTrials.gov